Steve King formed 21159Pharma in 2017 after working for 30 years in business development and CMC drug development. He has extensive experience in licensing and drug development in small molecules for NDAs (with a focus on orphan drug development) 505B2s and ANDA products — from early stage development through to commercialization. Steve has a unique combination of practical real-world experience of business and CMC drug development.